08.05.19

Alimera Announces Iluvien Regulatory Approval in Australia for the Treatment of DME

Source: Alimera Sciences

08.01.19

Perspective: Protocol V Sheds Light on Managing Mild Diabetic Macular Edema

Source: Medscape

07.29.19

Kodiak Sciences Announces Positive Interim Data from Phase 1b Study of KSI-301, a Novel Anti-VEGF Antibody Biopolymer Conjugate for Treatment of Retinal Diseases

Source: Kodiak Sciences

06.06.19

Phase 1/2 Study Evaluating THR-317 for DME Meets Primary Safety Endpoint

Source: Oxurion NV

06.04.19

Verseon Showcases Oral Candidates for Next-Generation Diabetic Eye Disease Drugs

Source: Verseon

05.22.19

Alimera Sciences Announces Launch of Direct-to-Patient Marketing Campaign for Iluvien

Source: Alimera Sciences

05.10.19

Watchful Waiting OK in Diabetic Macular Edema With Good Vision

Source: Medscape

05.08.19

Oxurion Issues Financial and Business Update

Source: Oxurion NV

04.30.19

Verseon Presents Oral Drug Candidate for Diabetic Eye Disease

Source: Verseon

04.25.19

Full Phase 2 Results Published Showing Efficacy, Safety, & Durability of Faricimab in DME

Source: Roche

View more stories